
10x Genomics (TXG) announced two new research collaborations focused on identifying blood-based biomarkers of disease activity and treatment response for autoimmune disease. The first collaboration is with Charite – Universitatsmedizin
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| TXG | 10x Genomics | 56.30 | 40.74 | 261.83% |
| Name | Price | % Change | |
|---|---|---|---|
| $56.30 | +261.83% |

10x Genomics (TXG) announced two new research collaborations focused on identifying blood-based biomarkers of disease activity and treatment response for autoimmune disease. The first collaboration is with Charite – Universitatsmedizin

10X Genomics (($TXG)) has held its Q3 earnings call. Read on for the main highlights of the call. Management at 10x Genomics struck a strongly positive tone, citing stronger revenue

JPMorgan lowered the firm’s price target on 10x Genomics (TXG) to $65 from $70 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate source

BofA lowered the firm’s price target on 10x Genomics (TXG) to $65 from $80 and keeps a Neutral rating on the shares. The firm says the company’s showed progress ahead

10X Genomics (TXG) has disclosed a new risk, in the Accounting & Financial Operations category. 10X Genomics faces rising legal, accounting and compliance costs as a public company, with management

UBS analyst Doug Schenkel lowered the firm’s price target on 10x Genomics (TXG) to $61 from $90 and keeps a Neutral rating on the shares. Published first on TheFly –

TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $55 from $70 and keeps a Hold rating on the shares.The firm updated its model

UBS lowered the firm’s price target on 10x Genomics (TXG) to $61 from $90 and keeps a Neutral rating on the shares. 10x Genomics delivered largely in-line results with upside

Stifel raised the firm’s price target on 10x Genomics (TXG) to $68 from $50 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source

Citi raised the firm’s price target on 10x Genomics (TXG) to $60 from $50 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate source
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Reiterated | Nov 11, 2026 | ||||
| hold | Assigned | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| hold | Assigned | Nov 9, 2026 | ||||
| hold | Reiterated | Nov 6, 2026 | ||||
| hold | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| hold | Reiterated | Nov 6, 2026 | ||||
| hold | Reiterated | Nov 6, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 17, 2027TBA | $7.23B | $-0.22 | $177.74M | 0.61 | -106.38 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.